Drugs / ∆9-tetrahydrocannabidiol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05351905 | Nov 2022 → Dec 2025 | chronic pain syndrome | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ∆9-tetrahydrocannabidiol | “MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation” NCT05351905 ↗ |
| Known as | THC | “MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation” NCT05351905 ↗ |
| Route | Oral | “oral formulation” NCT05351905 ↗ |